NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Winston Pharmaceuticals, Inc. ("Winston"), a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the National Institutes of Health (NIH) has awarded Winston a grant under the Small Business Innovation Research (SBIR) program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). The Phase I award in the amount of approximately $375,000 will be administered by the National Institute of Neurological Disorders and Stroke (NINDS).

“We are extremely pleased by the award of this SBIR grant”

"We are extremely pleased by the award of this SBIR grant," said Joel E. Bernstein, M.D., President and CEO of Winston. "The development of civamide nasal solution for treatment of PHN of the trigeminal nerve could bring relief to many patients suffering with this severe chronic pain. The use of TRPV-1 modulators in treating neuropathic disease is a unique approach in this area, and this SBIR grant gives us an opportunity to further investigate the use of this class of medications. The availability of an effective and safe treatment, i.e., without systemic effects or drug interactions, would fill an important unmet medical need in the treatment of PHN of the TN."

Source:

 Winston Pharmaceuticals

Comments

  1. TN
    Ang Ang United States says:

    I am not a dr., I want you to know that I appreciate this info as I have TN and had cyberknife surgery last year.  Unfortunately, my face is numb and I am getting pain on the other side of my face.  Drs. told me that this is very unusal. Any research and new developments I would be interested in the outcome; with this being said, thank for this article.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study reveals antiviral properties of glycosaminoglycans against SARS-CoV-2